Research ArticleBRAIN
T1 Hyperintensity in the Pulvinar: Key Imaging Feature for Diagnosis of Fabry Disease
Jun-ichi Takanashi, A. James Barkovich, William P. Dillon, Elliott H. Sherr, Kimberly A. Hart and Seymour Packman
American Journal of Neuroradiology May 2003, 24 (5) 916-921;
Jun-ichi Takanashi
A. James Barkovich
William P. Dillon
Elliott H. Sherr
Kimberly A. Hart
References
- ↵Desnick RJ, Ioannou YA, Eng CM. α-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill;2001 :3733–3774
- ↵deVeber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 1992;31:409–415
- ↵Kaye EM, Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23:505–509
- ↵Rahman AN, Lindenberg R. The neuropathology of hereditary dystropic lipidosis. Arch Neurol 1963;9:373–385
- ↵Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746–1749
- ↵Morgan SH, Rudge P, Smith SJM, et al. The neuropathological complications of Anderson-Fabry disease (α-galactosidase A deficiency): investigation of symptomatic and presymptomatic patients. Q J Med 1990;75:491–504
- ↵Scully RE, Mark EJ, McNeely BU. Case records of the Massachusetts General Hospital. N Engl J Med 1984;310:106–114
- ↵Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996;40:8–17
- ↵Aoki S, Okada Y, Nishimura K, et al. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology 1989;172:381–385
- ↵Barkovich AJ. MR and CT evaluation of profound neonatal and infantile asphyxia. AJNR Am J Neuroradiol 1992;13:959–972
- ↵Li JY, Lai PH, Chen CY, Wang JS, Lo YK. Postanoxic Parkinsonism: clinical, radiologic, and pathologic correlation. Neurology 2000;55:591–593
- ↵Yagishita A, Nakano I, Ushioda T, et al. Acute encephalopathy with bilateral thalamotegmental involvement in infants and children: imaging and pathology findings. AJNR Am J Neuroradiol 1995;16:439–447
- ↵
- ↵Kendall BE. Disorders of lysosomes, peroxisomes, and mitochondria. AJNR Am J Neuroradiol 1992;13:621–653
- ↵Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jacob disease. Lancet 2000;335:1412–1418
- ↵Collie DA, Sellar RJ, Zeidler M, et al. MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clin Radiol 2001;56:726–739
- ↵Henkelman RM, Watts JF, Kucharczyk W. High signal intensity in MR images of calcified brain tissue. Radiology 1991;179:199–206
- ↵Ho VB, Fitz CR, Chuang SH, Geyer CA. Bilateral basal ganglia lesions: pediatric differential considerations. Radiographics 1993;13:269–292
- ↵Shanley DJ. Meneralizing microangiopathy: CT and MRI. Neuroradiology 1995;37:331–333
- ↵Gomori JM, Grossman RI. Mechanisms responsible for MR appearance and evolution of intracranial hemorrhage. Radiographics 1988;8:427–440
- ↵Atlas SW, Grossman RI, Gomori JM, et al. MR imaging of the intracranial metastatic melanoma. J Comput Assist Tomogr 1987;11:577–582
- ↵Boyko OB, Burger PC, Shelburne JD, Ingram P. Non-heme mechanisms for T1 shortening: pathologic, CT, and MR elucidation. AJNR Am J Neuroradiol 1992;13:1439–1445
- ↵Tedeschi G, Bonavita S, Banerjee TK, et al. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 1999;52:1663–1667
- ↵Vymazal J, Righini A, Brooks RA, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999;211:489–495
- ↵Ward R, Danziger S, Owen V, Rafal R. Deficits in special coding and feature binding following damage to spatiotopic maps in the human pulvinar. Nat Neurosci 2002;5:99–100
- ↵Brady RO, Murray GJ, Moore DF, Schiffmann R. Enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2001;24:18–24
- Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9–16
- ↵Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease: a randomized control trial. JAMA 2001;285:2743–2749
- ↵Moore DF, Scott LTC, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104:1506–1512
- ↵Morgan SH, Crawfurd Md’A. Anderson-Fabry disease: a commonly missed diagnosis. BMJ 1988;297:872–873
In this issue
Advertisement
T1 Hyperintensity in the Pulvinar: Key Imaging Feature for Diagnosis of Fabry Disease
Jun-ichi Takanashi, A. James Barkovich, William P. Dillon, Elliott H. Sherr, Kimberly A. Hart, Seymour Packman
American Journal of Neuroradiology May 2003, 24 (5) 916-921;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Novel GLA T194A variant causes Fabry disease
- Redefining the Pulvinar Sign in Fabry Disease
- Brain MR Imaging Findings of Cardiac-Type Fabry Disease with an IVS4+919G>A Mutation
- Brain Magnetic Resonance Imaging Findings Fail to Suspect Fabry Disease in Young Patients With an Acute Cerebrovascular Event
- Pulvinar: Associative role in cortical function and clinical correlations
- Cerebrovascular Involvement in Fabry Disease: Current Status of Knowledge
- Voxel based analyses of diffusion tensor imaging in Fabry disease
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
More in this TOC Section
Similar Articles
Advertisement